Crossmark

Scaling up an intervention to protect preterm infants from neurodevelopmental disabilities — findings from a qualitative process evaluation comparing standard with enhanced quality improvement support packages for maternity units in England

Crossref DOI link: https://doi.org/10.1186/s13012-023-01275-2

Published Online: 2023-05-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Redwood, Sabi http://orcid.org/0000-0002-2159-1482
Pithara-McKeown, Christalla

Stone, Tracey

Treloar, Emma

Donovan, Jenny L.

Luyt, Karen
Funding

Funding for this research was provided by:

National Institute for Health Research Applied Research Collaboration West (NIHR200181)

The Health Foundation UK (reference 557668)

South West Academic Health Science Network
License Information

Text and Data Mining valid from 2023-05-24

Version of Record valid from 2023-05-24
More Information

Article History

Received: 26 September 2022

Accepted: 5 May 2023

First Online: 24 May 2023

Declarations

:

: The PReCePT study — a cluster randomised trial evaluating the impact of an enhanced support implementation of the PReCePT quality improvement toolkit to increase the uptake of magnesium sulphate in preterm deliveries for the prevention of neurodisabilities, was granted a favourable ethical opinion by the National Research Ethics Service (REC reference: 19/HRA/0323). The PReCePT Programme Evaluation was granted a favourable ethical opinion by the Faculty of Health Sciences Research Ethics Committee at the University of Bristol (FREC ID: 84582).

: Interview excerpts are presented anonymously.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below